Novo Nordisk Hit With Antitrust Action Over Prandin
Novo Nordisk A/S has been slapped with a putative class action that accuses it of attempting to monopolize the market for popular diabetes treatment Prandin by pursuing sham infringement litigation against...To view the full article, register now.
Already a subscriber? Click here to view full article